2026年5月27日，On May 27, 2026, Wang Changwei, Deputy Director of the Ningbo Municipal Bureau of Economy and Information Technology, Xu Yan, Director of the Biopharmaceutical Division, and Lu Zhanpeng, Deputy Director of the Biopharmaceutical Division, visited Zhejiang Tianyuan Biotechnology Co., Ltd. for inspection and guidance. Chairman Huang Bisheng, Group Chief Administrative Officer Zhu Youwu, and General Manager Jiao Mingming warmly received them and accompanied them throughout the visit.

      The leaders conducted an on-site tour of the company's science and technology exhibition hall, gaining a detailed understanding of the company's development history, core technology R&D, business layout, and future strategic planning. During the tour, Chairman Huang Bisheng gave a detailed report on the company's innovative practices in the biotechnology field in recent years, its breakthroughs in iPS cell technology, and its progress in industrialization applications.

      Deputy Director Wang Changwei fully affirmed Tianyuan Biotechnology's innovative exploration and R&D achievements in the biotechnology field. He noted that Tianyuan Biotechnology adheres to an innovation-driven development path and has devoted itself to the life and health sector, achieving positive results in technological R&D and the translation of achievements, thereby injecting new momentum into the high-quality development of Ningbo's biopharmaceutical industry.

      On behalf of the company, Chairman Huang Bisheng expressed sincere gratitude to the leaders of the Municipal Bureau of Economy and Information Technology for their care and support. He stated that Tianyuan Biotechnology will take this opportunity to continue focusing on the health industry track, increase R&D investment, deepen technological innovation, and continuously enhance its core competitiveness, actively integrating into the overall development of Ningbo's biopharmaceutical industry and making greater contributions to the high-quality development of the local economy.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to the integrated development of cell R&D, production, operations, and services. It holds valuable resource banks including an HLA umbilical cord matching bank, an iPS seed cell bank, and a tumor cell bank, and serves as a formulating unit for the group standard on immune function assessment methods under the National Health Commission. The company has jointly established a Metabolic and Immune Monitoring Joint Laboratory with the Institute of Science and Technology of the National Health Commission, and also serves as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Translation Center of the Institute of Science and Technology of the National Health Commission, among other important research and service platforms.